Rübe et al. have shown for non-small cell lung cancer (NSCLC) that the tumor itself is the major source of plasma IL-6; however, we cannot conclusively prove that the measured plasma IL-6 only derive from tumor cells in this trial [51]. This evidence concerns the gene IL6 and neoplasm.